Viqar Syed, Ph.D

Viqar Syed, Ph.D

Name: Viqar Syed, Ph.D

USU Department of Primary Appointment: 
Obstetrics and Gynecology
Faculty Rank: 
Associate Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD

Research Interests:
Develop novel therapeutic strategies for advanced and recurrent ovarian and endometrial cancer
Understand the molecular mechanism of carcinogenesis

Office Phone: 
(301) 295-3128

Education

BS. Biology, Chemistry, University of Punjab, Lahore, Pakistan
MS. Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
M.Phil. Reproductive Endocrinology, Quaid-i-Azam University, Islamabad, Pakistan
Ph.D. Reproductive Endocrinology, Karolinska Institute, Stockholm, Sweden

Biography

Dr. Syed received her PhD in Reproductive Endocrinology from the Karolinska Institute, Stockholm, Sweden and did postdoctoral training at the Max Planck Clinical Research Unit for Reproductive Medicine in Münster, Germany and at the University of Rennes, France. Syed’s research focuses on the molecular mechanisms that control cell growth and proliferation, and in understanding how these mechanisms are disrupted in ovarian and endometrial cancer cells. The goal is to identify molecules or signaling pathways that play an essential role in the acquisition of a metastatic phenotype and to understand their mechanisms of action. From a translational standpoint, the aim is to develop novel targets to predict or to treat cancer. In addition, state-of-the-art techniques of cell culture, molecular biology, gene profiling, proteomics and animal models are used to determine the mechanisms through which progesterone and vitamin-D combination offers protection against the development of gynecological tumors. Dr. Syed has published over 60 articles in various peer-reviewed journals including the Journal of the National Cancer Institute, Cancer Research, Oncogene, Molecular Cancer Research, Oncotarget and Molecular Therapeutics. Dr. Syed has been an active member in several scientific review panels, including the Cancer Prevention Research Study Section of the National Cancer Institute and the Department of Defense Ovarian and Prostate Cancer Research Programs.

Representative publications, projects, and/or deployments

  • Hope ER, Hamilton CA, Mhawech-Fauceglia P, Pejovic T, Maxwell GL, Syed V, Darcy KM (2016). Nestin Commentary. Current Trends in Gynecologic Oncology. Volume 1, Issue 2. 1000108.
  • Bokhari AA, Baker TM, Dorjbal B, Waheed S, Zahn CM, Hamilton CA, Maxwell GL, Syed V (2016). Nestin Suppression Attenuates Invasive Potential of Endometrial Cancer Cells by Down Regulating TGF -β Signaling Pathway. Oncotarget. 2016;7:69733-69748.
  • Hope ER, Mhawech-Fauceglia P, Pejovic T, Zahn CM, Wang G, Conrads TP, Maxwell GL, Hamilton CA, Darcy KM, Syed V (2016). Nestin: a biomarker of aggressive uterine cancers. Gynecologic Oncology. 140: 503–511
  • Bokhari AA, Lee LR, Raboteau D, Turbov J, Rodriguez IV, Pike JW, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V (2016). Progesterone Potentiates the Growth Inhibitory Effects of Calcitriol in Endometrial Cancer via Suppression of CYP24A1. Oncotarget;7:77576-77590.